ddd-20210630

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________to____________

Commission File No. 001-34220

__________________________

3D SYSTEMS CORPORATION

(Exact name of Registrant as specified in its Charter)

__________________________


Delaware			95-4431352
(State or Other Jurisdiction of Incorporation or Organization)			(I.R.S. Employer Identification No.)

333 Three D Systems Circle

Rock Hill, South Carolina 29730

(Address of Principal Executive Offices and Zip Code)

(Registrant’s Telephone Number, Including Area Code): (803) 326-3900

_________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, par value $0.001 per share

DDD

New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☒

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ☐ No ☒

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Shares of Common Stock, par value $0.001 per share, outstanding as of August 5, 2021: 125,235,532

3D SYSTEMS CORPORATION

Form 10-Q

For the Quarter Ended June 30, 2021

TABLE OF CONTENTS


PART I — FINANCIAL INFORMATION
Item 1. Financial Statements.			3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.			25
Item 3. Quantitative and Qualitative Disclosures About Market Risk.			33
Item 4. Controls and Procedures.			34
PART II — OTHER INFORMATION
Item 1. Legal Proceedings.			34
Item 1A. Risk Factors.			34
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.			35
Item 6. Exhibits.			36

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements.

3D SYSTEMS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS


(In thousands, except par value)	June 30, 2021 (unaudited)		December 31, 2020
ASSETS
Current assets:
Cash and cash equivalents	$	131,844	$	75,010
Accounts receivable, net of reserves — $4,183 and $4,392	88,618		114,254
Inventories	102,961		116,667
Prepaid expenses and other current assets	33,251		33,145
Current assets held for sale	14,240		18,439

Total current assets	370,914		357,515
Property and equipment, net	59,183		75,356
Intangible assets, net	33,306		28,083
Goodwill	146,267		161,765
Right of use assets	47,490		48,620
Deferred income tax asset	5,146		6,247
Assets held for sale	28,916		31,684
Other assets	21,071		23,785
Total assets	$	712,293	$	733,055
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	—	$	2,051
Current right of use liabilities	8,256		9,534
Accounts payable	47,979		45,174
Accrued and other liabilities	62,568		69,812

Customer deposits	7,547		7,750
Deferred revenue	28,727		30,302
Current liabilities held for sale	3,813		11,107
Total current liabilities	158,890		175,730
Long-term debt, net of deferred financing costs	—		19,218
Long-term right of use liabilities	47,793		48,469
Deferred income tax liability	3,487		4,716
Liabilities held for sale	2,926		2,952
Other liabilities	32,658		51,247
Total liabilities	245,754		302,332

Commitments and contingencies (Note 14)

Stockholders’ equity:
Common stock, $0.001 par value, authorized 220,000 shares; issued 126,796 and 127,626	127		128
Additional paid-in capital	1,407,900		1,404,964
Treasury stock, at cost — 1,623 shares and 3,494 shares	(10,492)		(22,590)
Accumulated deficit	(907,707)		(943,303)
Accumulated other comprehensive loss	(23,289)		(8,476)
Total stockholders’ equity	466,539		430,723
Total liabilities and stockholders’ equity	$	712,293	$	733,055

See accompanying notes to condensed consolidated financial statements.

3D SYSTEMS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)


	Quarter Ended June 30,				Six Months Ended June 30,
(in thousands, except per share amounts)	2021		2020		2021		2020
Revenue:
Products	$	108,638	$	62,213	$	202,286	$	141,952
Services	53,919		50,564		106,387		106,460
Total revenue	162,557		112,777		308,673		248,412
Cost of sales:
Products	62,635		51,284		115,999		99,738
Services	30,917		26,326		59,429		56,375
Total cost of sales	93,552		77,610		175,428		156,113
Gross profit	69,005		35,167		133,245		92,299
Operating expenses:
Selling, general and administrative	61,463		52,042		111,063		108,148
Research and development	17,602		16,997		34,201		36,241

Total operating expenses	79,065		69,039		145,264		144,389
Loss from operations	(10,060)		(33,872)		(12,019)		(52,090)
Interest and other income (expense), net	(316)		(2,615)		38,537		(5,179)
Income (loss) before income taxes	(10,376)		(36,487)		26,518		(57,269)
Benefit (provision) for income taxes	744		(1,464)		9,078		394
Net income (loss)	$	(9,632)	$	(37,951)	$	35,596	$	(56,875)



Net income (loss) per common share:
Basic	$	(0.08)	$	(0.33)	$	0.29	$	(0.49)
Diluted	$	(0.08)	$	(0.33)	$	0.28	$	(0.49)

Weighted average shares outstanding:
Basic	122,147		115,503		121,931		115,047
Diluted	122,147		115,503		125,069		115,047

See accompanying notes to condensed consolidated financial statements.

3D SYSTEMS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited)


	Quarter Ended June 30,				Six Months Ended June 30,
(in thousands)	2021		2020		2021		2020
Net income (loss)	$	(9,632)	$	(37,951)	$	35,596	$	(56,875)
Other comprehensive income (loss), net of taxes:
Pension adjustments	28		13		209		177
Derivative financial instruments	—		1,235		721		(424)
Foreign currency translation	3,385		7,037		(22,224)		(3,135)
Foreign currency translation reclassification - sale of Cimatron	—		—		6,481		—
Total other comprehensive income (loss), net of taxes	3,413		8,285		(14,813)		(3,382)
Total comprehensive income (loss), net of taxes	$	(6,219)	$	(29,666)	$	20,783	$	(60,257)

See accompanying notes to condensed consolidated financial statements.

3D SYSTEMS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Six Months Ended June 30,
(in thousands)	2021		2020
Cash flows from operating activities:
Net income (loss)	$	35,596	$	(56,875)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	17,890		23,059
Stock-based compensation	30,576		13,606
Unrealized gain on exchange rate	(2,100)		—
Provision for inventory obsolescence and revaluation	1,100		10,894
Loss on hedge accounting de-designation and termination	721		1,235
Provision for bad debts	800		1,198
Gain on the disposition of businesses, property, equipment and other assets	(37,240)		(134)
Provision for deferred income taxes and reserve adjustments	(9,014)		(671)
Impairment of goodwill and assets	—		1,100
Changes in operating accounts:
Accounts receivable	12,476		12,639
Inventories	9,132		(24,544)
Prepaid expenses and other current assets	(1,065)		(19,976)
Accounts payable	3,424		2,470
Deferred revenue and customer deposits	(531)		6,678
Accrued and other liabilities	(23,020)		3,637
All other operating activities	3,231		4,666
Net cash provided by (used in) operating activities	41,976		(21,018)
Cash flows from investing activities:
Purchases of property and equipment	(8,204)		(7,162)
Proceeds from sale of assets and businesses, net of cash	54,747		552
Business acquisitions, net of cash acquired	(10,912)		—
Purchase of noncontrolling interest	(4,000)		(12,500)
Other investing activities	(306)		(474)
Net cash provided by (used in) investing activities	31,325		(19,584)
Cash flows from financing activities:



Repayment of borrowings/long-term debt	(21,392)		(26,254)

Proceeds from inventory financing agreements	—		2,509

Payments related to net-share settlement of stock-based compensation	(6,629)		(3,821)
Other financing activities	(423)		296
Net cash used in financing activities	(28,444)		(27,270)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	2,902		(1,856)
Net increase (decrease) in cash, cash equivalents and restricted cash	47,759		(69,728)
Cash, cash equivalents and restricted cash at the beginning of the period (a)	84,711		134,617
Cash, cash equivalents and restricted cash at the end of the period (a)	$	132,470	$	64,889


Supplemental cash flow information
Lease assets obtained in exchange for new lease liabilities (excludes adoption)	$	6,026	$	16,238
Cash interest payments	$	1,058	$	1,519
Cash income tax payments, net	$	3,303	$	2,617
Transfer of equipment from inventory to property and equipment, net (b)	$	(76)	$	575
Stock issued for acquisition	$	3,500	$	—

a.The amounts for cash and cash equivalents shown above include restricted cash of $626 and $967 as of June 30, 2021 and 2020, respectively, and $540 and $952 as of December 31, 2020, and 2019, respectively, which were included in Other assets, net, and $9,161 as of December 31, 2020, which was included in Current assets held for sale in the condensed consolidated balance sheets.

b.Inventory is transferred from inventory to property and equipment at cost when we require additional machines for training or demonstration or for placement into on-demand manufacturing services locations.

See accompanying notes to condensed consolidated financial statements.

3D SYSTEMS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Unaudited)


	Quarters Ended June 30, 2021 and 2020
	Common Stock
(in thousands, except par value)	Par Value $0.001		Additional Paid In Capital		Treasury Stock		Accumulated Deficit		Accumulated Other Comprehensive Income (Loss)		Total Stockholders' Equity
March 31, 2021	$	126	$	1,397,276	$	(10,492)	$	(898,075)	$	(26,702)	$	462,133
Payments related to net-share settlement of stock-based compensation	1		(3,881)		—		—		—		(3,880)

Shares issued to acquire assets and businesses	—		3,500		—		—		—		3,500
Stock-based compensation expense	—		11,005		—		—		—		11,005
Net loss	—		—		—		(9,632)		—		(9,632)
Gain on pension plan - unrealized	—		—		—		—		28		28

Foreign currency translation adjustment	—		—		—		—		3,385		3,385
June 30, 2021	$	127	$	1,407,900	$	(10,492)	$	(907,707)	$	(23,289)	$	466,539

March 31, 2020	$	121	$	1,370,174	$	(19,718)	$	(812,633)	$	(49,275)	$	488,669
Repurchase of stock	3		—		(2,872)		—		—		(2,869)
Stock-based compensation expense	—		7,294		—		—		—		7,294
Net loss	—		—		—		(37,951)		—		(37,951)
Pension adjustment	—		—		—		—		13		13
Derivative financial instrument gain	—		—		—		—		1,235		1,235
Foreign currency translation adjustment	—		—		—		—		7,037		7,037
June 30, 2020	$	124	$	1,377,468	$	(22,590)	$	(850,584)	$	(40,990)	$	463,428

See accompanying notes to condensed consolidated financial statements.

3D SYSTEMS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Continued)

(Unaudited)


	Six Months Ended June 30, 2021 and 2020
	Common Stock
(in thousands, except par value)	Par Value $0.001		Additional Paid In Capital		Treasury Stock		Accumulated Deficit		Accumulated Other Comprehensive Income (Loss)		Total 3D Systems Corporation Stockholders' Equity		Equity Attributable to Noncontrolling Interests		Total Stockholders' Equity
December 31, 2020	$	128	$	1,404,964	$	(22,590)	$	(943,303)	$	(8,476)	$	430,723	$	—	$	430,723
Repurchase of stock	1		(6,630)		—		—		—		(6,629)		—		(6,629)
Shares issued to acquire assets and businesses	—		3,500		—		—		—		3,500		—		3,500
Stock-based compensation expense	—		18,162		—		—		—		18,162		—		18,162
Net income	—		—		—		35,596		—		35,596		—		35,596
Pension Adjustment	—		—		—		—		181		181		—		181
Gain on pension plan - unrealized	—		—		—		—		28		28		—		28
Termination of derivative instrument	—		—		—		—		721		721		—		721
Retirement of treasury shares	(2)		(12,096)		12,098		—		—		—		—		—
Foreign currency translation adjustment	—		—		—		—		(15,743)		(15,743)		—		(15,743)
June 30, 2021	$	127	$	1,407,900	$	(10,492)	$	(907,707)	$	(23,289)	$	466,539	$	—	$	466,539

December 31, 2019	$	120	$	1,371,564	$	(18,769)	$	(793,709)	$	(37,047)	$	522,159	$	(8,263)	$	513,896
Repurchase of stock	4		—		(3,821)		—		—		(3,817)		—		(3,817)
Acquisition of non-controlling interest	—		(7,702)		—		—		(561)		(8,263)		8,263		—
Stock-based compensation expense	—		13,606		—		—		—		13,606		—		13,606
Net loss	—		—		—		(56,875)		—		(56,875)		—		(56,875)
Pension adjustment	—		—		—		—		177		177		—		177
Derivative financial instrument loss	—		—		—		—		(1,659)		(1,659)		—		(1,659)
De-designation of derivative instrument	—		—		—		—		1,235		1,235		—		1,235
Foreign currency translation adjustment	—		—		—		—		(3,135)		(3,135)		—		(3,135)
June 30, 2020	$	124	$	1,377,468	$	(22,590)	$	(850,584)	$	(40,990)	$	463,428	$	—	$	463,428

See accompanying notes to condensed consolidated financial statements.

3D SYSTEMS CORPORATION

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(1) Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the accounts of 3D Systems Corporation and all majority-owned subsidiaries and entities in which a controlling interest is maintained (“3D Systems” or the “Company” or “we” or “us”). All significant intercompany transactions and balances have been eliminated in consolidation.

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim reports. Accordingly, they do not include all the information and notes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 (“2020 Form 10-K”). Our annual reporting period is the calendar year.

In the opinion of management, the unaudited condensed consolidated financial statements contain all adjustments, consisting of adjustments of a normal recurring nature, necessary to present fairly the financial position, results of operations and cash flows for the periods presented. The results of operations for the quarter and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results may differ from those estimates and assumptions.

As we continue to closely monitor the COVID-19 pandemic, our top priority remains the health and safety of our employees and their families and communities. Our Crisis Response Steering Committee regularly reviews and adapts our protocols based on evolving research and guidance related to the virus. While essential operations continue, we continue to restrict travel and meetings, publish pertinent information, and adapt to a world where many in our workforce are remote and those coming on-site are following new safety measures. In certain of our locations, where local conditions and regulation allow, our employees have begun to return to working on-site. We continue to watch conditions and regulations and remain committed to protecting our employees, delivering for our customers and supporting our communities.

Our operations in North America and South America (collectively referred to as “Americas”), Europe and the Middle East (collectively referred to as “EMEA”) and the Asia Pacific region (“APAC”) expose us to risks associated with public health crises and epidemics/pandemics, such as the COVID-19 pandemic. While the COVID-19 pandemic continued to impact our reported results for the quarter ended June 30, 2021, we are unable to predict the longer-term impact that the pandemic may have on our business, results of operations, financial position or cash flows. The extent to which our operations may be impacted by the dynamic nature of the COVID-19 pandemic will depend largely on future developments, which are highly uncertain and cannot be accurately predicted, including the severity or resurgence of the outbreak and actions by government authorities to contain the outbreak or treat its impact. Furthermore, the impacts of uncertain global economic conditions, further supply chain disruptions, including the shortages of critical components, and the continued disruptions to, and volatility in, the financial markets remain unknown.

As of January 1, 2021, we determined the Company has two reportable segments, Healthcare and Industrial; whereas, the Company previously only reported its consolidated results in one segment. This change in segment reporting as of January 1, 2021 was the result of changes to how the chief operating decision maker ("CODM") assesses the financial performance of the Company and in the decision-making process driving future operating performance. As a result of this re-segmentation, the Company performed a quantitative analysis for potential impairment of our goodwill immediately following the re-segmentation. Based on available information and analysis as of January 1, 2021, we determined the fair value of the Healthcare and Industrial reporting units exceeded their carrying values.

Fair value was determined using a combination of an income approach, which estimates fair value based upon projections of future revenues, expenses, and cash flows discounted to its present value, and a market approach. The valuation methodology and underlying financial information included in the Company's determination of fair value required significant judgments by management. The principal assumptions used in the Company's discounted cash flow analysis consisted of (a) the long-term projections of future financial performance and (b) the weighted-average cost of capital of market participants, adjusted for the risk attributable to the Company and the industry in which it operates. Under the market approach, the principal assumption included an estimate for a control premium.

All dollar amounts presented in the accompanying footnotes are presented in thousands, except for per share information.

During the first quarter ended March 31, 2021 we became aware that certain amounts previously presented within our statements of operations as products cost of sales related to services cost of sales. We note that the total cost of sales line item was not affected. We further note that this error did not affect our gross profit, loss from operations, net income (loss), consolidated balance sheets or statements of cash flow. We evaluated the materiality of this presentation-only error and concluded it was not material to any previously reported quarter or year-end financial statement. The following schedule depicts the effect on our previously reported statements of operations.


	Quarter Ended June 30, 2020						Six Months Ended June 30, 2020
(in thousands)	As reported		Change		Revised		As reported		Change		Revised
Cost of sales:
Products	$	53,204	$	(1,920)	$	51,284	$	103,030	$	(3,292)	$	99,738
Services	24,406		1,920		26,326		53,083		3,292		56,375
Total cost of sales	$	77,610	$	—	$	77,610	$	156,113	$	—	$	156,113

Recently Adopted Accounting Standards

In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, “Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes,” which simplifies the accounting for income taxes by eliminating some exceptions to the general approach in Accounting Standards Codification 740, Income Taxes. It also clarifies certain aspects of the existing guidance to promote more consistent application. This standard is effective for calendar-year public business entities in 2021 and interim periods within that year, and early adoption is permitted. The Company adopted this guidance during the first quarter of 2021. The implementation did not have a material effect on our financial position or results of operations.

No other new accounting pronouncements, issued or effective during 2021, have had or are expected to have a significant impact on our consolidated financial statements.

(2) Dispositions and Acquisitions

Dispositions

On January 1, 2021, the Company completed the sale of 100% of the issued and outstanding equity interests of Cimatron Ltd. ("Cimatron"), the subsidiary that operated the Company’s Cimatron integrated CAD/CAM software for tooling business and its GibbsCAM CNC programming software business, for approximately $64,173, after certain adjustments and excluding $9,476 of cash amounts transferred to the purchaser. We recorded a gain on the sale of $32,928 included within Interest and other income (expense), net on the accompanying condensed consolidated statements of operations for the six months ended June 30, 2021. Additionally, at the time of the sale, we recognized a gain of $6,481 for accumulated foreign currency translation gain previously included in Accumulated other comprehensive loss ("AOCL"), which is included within Interest and other income (expense), net. We are finalizing closing adjustments with the purchaser. This disposed of business would have been included within the Industrial segment.

On June 1, 2021, the Company entered into an Asset Purchase Agreement with QP 3D Acquisition, Inc., an affiliate of Trilantic North America (the “Purchaser”), pursuant to which the Purchaser agreed to purchase from the Company (the “Transaction”), the Company’s On Demand Manufacturing business (“ODM”), for a purchase price of $82,000 subject to certain closing adjustments. Completion of the Transaction is expected to occur during the third quarter of 2021. At closing, the Company and the Purchaser will enter into a transition services agreement pursuant to which the Company and certain of its affiliates will provide certain information technology, corporate finance, tax, treasury, accounting, human resources and payroll, sales and marketing, operations, facilities and other customary services to support the Purchaser in the ongoing operation of ODM. The assets and liabilities of ODM were reclassified to held for sale on the consolidated balance sheet as of June 30, 2021.

The components of ODM's assets and liabilities recorded as held for sale on the consolidated balance sheet at June 30, 2021 were as follows:


(in thousands)	June 30, 2021
Assets
Accounts receivable, net of reserves of $463	$	11,529
Inventories	2,017
Prepaid expenses and other current assets	694

Total current assets held for sale	14,240
Property and equipment, net	10,740
Intangible assets, net	2,491
Goodwill	13,306
Right of use assets	2,234
Other assets	145
Total assets held for sale	$	43,156
Liabilities
Current right of use liabilities	$	1,023
Accounts payable	496
Accrued and other liabilities	1,549

Customer deposits	745
Total current liabilities held for sale	3,813
Long-term right of use liabilities	1,629

Other liabilities	1,297
Total liabilities held for sale	$	6,739

Acquisitions

On May 6, 2021, we purchased Allevi, Inc. to expand regenerative medicine initiatives into medical and pharmaceutical research and development laboratories. Additionally, on June 15, 2021, we closed the acquisition of a German software firm, Additive Works GmbH. Additive Works expands the simulation capabilities for rapid optimization of industrial-scale 3D printing processes. The purchase price for both acquisitions, individually and combined, and the expected impacts on the Company's financial position, results of operations and cash flows are not material. We are in the process of finalizing the purchase accounting for both acquisitions and expect to finalize the purchase accounting in 2021.

Acquisitions of Noncontrolling Interests

As of June 30, 2020, we owned 100% of the capital and voting rights of Robtec, a service bureau and distributor of 3D printing and scanning products in Brazil. Approximately 70% of the capital and voting rights of Robtec were acquired on November 25, 2014. On January 7, 2020, we made a payment equal to the redemption price of $10,000 and acquired the remaining 30% of the capital and voting rights.

As of December 31, 2018, the Company owned approximately 70% of the capital and voting rights of Easyway, a service bureau and distributor of 3D printing and scanning products in China. Approximately 65% of the capital and voting rights of Easyway were acquired on April 2, 2015, and an additional 5% of the capital and voting rights of Easyway were acquired on July 19, 2017 for $2,300. The remaining 30% of the capital and voting rights of Easyway were acquired on January 21, 2019 for $13,500 to be paid in installments over four years for which $4,000 and $2,500 were paid in the first half of 2021 and 2020, respectively.

(3) Revenue

We account for revenue in accordance with ASC Topic 606, “Revenue from Contracts with Customers.”

Performance Obligations

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.

At June 30, 2021, we had $137,615 of outstanding performance obligations, comprised of deferred revenue, customer order backlog and customer deposits. We expect to recognize approximately 87% of our remaining performance obligations as revenue within the next twelve months, an additional 8% by the end of 2022 and the remaining balance thereafter.

Revenue Recognition

Revenue is recognized when control of the promised products or services is transferred to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. Many of our contracts with customers include multiple performance obligations. For such arrangements, we allocate revenue to each performance obligation based on its relative stand-alone selling price (“SSP”). Revenue is recognized net of allowances for returns and any taxes collected from customers, which are subsequently remitted to governmental authorities. The amount of consideration received and revenue recognized may vary based on changes in marketing incentive programs offered to our customers. Our marketing incentive programs take many forms, including volume discounts, trade-in allowances, rebates and other discounts.

A majority of our revenue is recognized at the point in time when products are shipped or services are delivered to customers. Please see below for further discussion.

Hardware and Materials

Revenue from hardware and material sales is recognized when control has transferred to the customer, which typically occurs when the goods have been shipped to the customer, risk of loss has transferred to the customer and we have a present right to payment. In limited circumstances, when printer or other hardware sales include substantive customer acceptance provisions, revenue is recognized either when customer acceptance has been obtained, customer acceptance provisions have lapsed, or we have objective evidence that the criteria specified in the customer acceptance provisions have been satisfied.

Printers and certain other products include a warranty under which we provide maintenance for periods up to one year. For these initial product warranties, estimated costs are accrued at the time of the sale of the product. These cost estimates are established using historical information on the nature, frequency and average cost of claims for each type of printer or other product as well as assumptions about future activity and events. Revisions to expense accruals are made as necessary based on changes in these historical and future factors.

Software

We also market and sell software tools that enable our customers to capture and customize content using our printers, design optimization and simulation software, and reverse engineering and inspection software. Software does not require significant modification or customization and the license provides the customer with a right to use the software as it exists when made available. Revenue from these software licenses is recognized either upon delivery of the product or of a key code which allows the customer to download the software. Customers may purchase post-sale support. Generally, the first year of post-sales support is included as part of the initial software sale but subsequent years are optional. This optional support is considered a separate obligation from the software and is deferred at the time of sale and subsequently recognized ratably over future periods.

Collaboration and Licensing Agreements

We enter into collaboration and licensing agreements with third parties. The nature of the activities to be performed and the consideration exchanged under the agreements varies on a contract-by-contract basis. We evaluate these agreements to determine whether they meet the definition of a customer relationship for which revenue is recorded. These contracts may contain multiple performance obligations and may contain fees for licensing, research and development services, contingent milestone payments upon the achievement of developmental contractual criteria and/or royalty fees based on the licensees’ product revenue. We determine the revenue to be recognized for these agreements based on an evaluation of the distinct performance obligations, the identification and evaluation of material rights, the estimation of variable consideration and the determination of the pattern on transfer of control for each distinct performance obligation. The Company recognized $2,040 and $717 in revenue related to collaboration arrangements with customers for the quarters ended June 30, 2021 and 2020, respectively. The Company recognized $3,847 and $1,647 in revenue related to collaboration arrangements with customers for the six months ended June 30, 2021 and 2020, respectively.

Services

We offer training, installation and non-contract maintenance services for our products. Additionally, we offer maintenance contracts customers can purchase at their option. For maintenance contracts, revenue is deferred at the time of sale based on the stand-alone selling prices of these services and costs are expensed as incurred. Deferred revenue is recognized ratably over the term of the maintenance period on a straight-line basis. Revenue from training, installation and non-contract maintenance services is recognized at the time of performance of the service.

On-demand manufacturing and healthcare service sales are included within services revenue and revenue is recognized upon shipment or delivery of the parts or performance of the service, based on the terms of the arrangement.

Terms of Sale

Shipping and handling activities are treated as fulfillment costs rather than as an additional promised service. We accrue the costs of shipping and handling when the related revenue is recognized. Our incurred costs associated with shipping and handling are included in product cost of sales.

Credit is extended, and creditworthiness is determined, based on an evaluation of each customer’s financial condition. New customers are generally required to complete a credit application and provide references and bank information to facilitate an analysis of creditworthiness. Customers with a favorable profile may receive credit terms that differ from our general credit terms. Creditworthiness is considered, among other things, in evaluating our relationship with customers with past due balances.

Our terms of sale generally provide payment terms that are customary in the countries where we transact business. To reduce credit risk in connection with certain sales, we may, depending upon the circumstances, require significant deposits, letters of credit or payment in full prior to shipment. For maintenance services, we either bill customers on a time-and-materials basis or sell maintenance contracts that provide for payment in advance on either an annual or other periodic basis.

Significant Judgments

Our contracts with customers often include promises to transfer multiple products and services to a customer. For such arrangements, we allocate revenues to each performance obligation based on its relative SSP.

Judgment is required to determine the SSP for each distinct performance obligation in a contract. For the majority of items, we estimate SSP using historical transaction data. We use a range of amounts to estimate SSP when we sell each of the products and services separately and need to determine whether there is a discount to be allocated based on the relative SSP of the various products and services. In instances where SSP is not directly observable, such as when the product or service is not sold separately, we determine the SSP using information that may include market conditions and other observable inputs.

In some circumstances, we have more than one SSP for individual products and services due to the stratification of those products and services by customers, geographic region or other factors. In these instances, we may use information such as the size of the customer and geographic region in determining the SSP.

The determination of SSP is an ongoing process and information is reviewed regularly in order to ensure SSP reflects the most current information or trends.

The nature of our marketing incentives may lead to consideration that is variable. Judgment is exercised at contract inception to determine the most likely outcome of the contract and resulting transaction price. Ongoing assessments are performed to determine if updates are needed to the original estimates.

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer deposits and deferred revenues (contract liabilities) on the condensed consolidated balance sheets. Timing of revenue recognition may differ from the timing of invoicing to customers. We record a receivable when revenue is recognized at the time of invoicing, or unbilled receivables when revenue is recognized prior to invoicing. For most of our contracts, customers are invoiced when products are shipped or when services are performed resulting in billed accounts receivables for the remainder of the owed contract price. Unbilled receivables generally result from items being shipped where the customer has not been charged, but for which revenue had been recognized. In our on-demand manufacturing business, customers may be required to pay in full before work begins on their orders, resulting in customer deposits. We typically bill in advance for installation, training and maintenance contracts as well as extended warranties, resulting in deferred revenue. Changes in contract asset and liability balances were not materially impacted by any other factors for the six months ended June 30, 2021.

For the six months ended June 30, 2021, we recognized revenue of $24,740 related to our contract liabilities at December 31, 2020. For the six months ended June 30, 2020, we recognized revenue of $21,103 related to our contract liabilities at December 31, 2019.

Practical Expedients and Exemptions

We generally expense sales commissions when incurred because the amortization period would be one year or less. These costs are recorded within selling, general and administrative expenses.

(4) Segment Information

Effective January 1, 2021, we changed our segment reporting under ASC 280 Segment Reporting. For periods prior to January 1, 2021, we operated under one operating segment, consistent with the information that was presented to our Chief Operating Decision Maker (CODM). Effective January 1, 2021, we have identified two operating segments, Healthcare and Industrial.

This change in reportable segments was necessitated as a result of changes to our enterprise wide financial reporting to reflect the re-organization of the business into the Healthcare and Industrial verticals that were launched January 1, 2021 at the request of our CODM. These changes resulted in revisions to the financial information provided to the CODM on a recurring basis in his evaluation of financial performance of the Company and in the decision-making process driving future operating performance. The CODM does not review disaggregated assets on a segment basis; therefore, such information is not presented. In addition, the changes made to our enterprise wide financial reporting system were prospective and prevent historical financial information for the Healthcare and Industrial segments to be available other than for revenue which has been disclosed below. We have evaluated potential alternatives to generate comparative prior period financial information for the Healthcare and Industrial segments, and believe that the practicality exception as proscribed in ASC 280 Segment Reporting is applicable due to the high degree of difficulty involved and the significant expense associated with overhauling the structure of legacy financial systems.

The following tables set forth our net sales and operating results by segment:


	Quarter Ended June 30,
	2021		2020		2021
(in thousands)	Net Sales (a)				Operating Profit
Operations by segment:
Healthcare	$	82,826	$	49,134	$	22,253
Industrial	79,731		63,643		9,858

Total	$	162,557	$	112,777	32,111
General corporate expense, net (b)					(42,171)
Operating loss, as reported					(10,060)
Interest and other expense, net					(316)
Loss before income taxes					$	(10,376)


	Six Months Ended June 30,
	2021		2020		2021
(in thousands)	Net Sales (a)				Operating Profit
Operations by segment:
Healthcare	$	155,347	$	101,426	$	42,046
Industrial	153,326		146,986		22,480

Total	$	308,673	$	248,412	64,526
General corporate expense, net (b)					(76,545)
Operating loss, as reported					(12,019)
Interest and other income, net					38,537
Income before income taxes					$	26,518

a.Approximately 43.9% and 50.7% for the quarters ended June 30, 2021 and 2020, respectively, and 43.8% and 52.3% of sales for the six months ended June 30, 2021 and 2020, respectively, were located outside of the U.S.

b.General corporate expense, net includes expenses not specifically attributable to our segments for functions such as corporate human resources, finance, and legal, including salaries, benefits, and other related costs.

(5) Leases

We have various lease agreements for our facilities, equipment and vehicles with remaining lease terms ranging from one to fifteen years. We determine if an arrangement contains a lease at inception. Some leases include the options to purchase, terminate or extend for one or more years; these options are included in the right-of-use (“ROU”) asset and liability lease term when it is reasonably certain an option will be exercised. Our leases do not contain any material residual value guarantees or material restrictive covenants.

Most of our leases do not provide an implicit rate; therefore, we use our incremental borrowing rate based on the information available at the commencement date to determine the present value of the future lease payments.

Certain of our leases include variable costs. Variable costs include non-lease components that were incurred based upon actual terms rather than contractually fixed amounts. In addition, incremental lease payments that are indexed to a change in rate or index are considered variable costs. Because the ROU asset and lease liability recorded on the balance sheet was determined based upon factors considered at the commencement date, subsequent changes in the rate or index that were not contemplated, result in variable expenses being incurred when actual payments differ from estimated payments.

On February 25, 2021, the Company entered into an agreement to amend its lease for its corporate office and extended the term. As part of this agreement, the Company sold land owned adjacent to our corporate office for $400 and entered into a lease with the buyer of the land for a new building, containing approximately 80,000 to 100,000 rentable square feet, to be constructed by the lessor. The initial lease terms for both the existing building and the expansion site extend through August 2037. The lease for the new building will not commence until construction is substantially complete.

Components of lease cost (income) were as follows:


	Quarter Ended June 30,				Six Months Ended June 30,
(in thousands)	2021		2020		2021		2020
Operating lease cost	$	2,669	$	2,999	$	5,182	$	6,007

Finance lease cost - amortization expense	156		220		306		435
Finance lease cost - interest expense	62		164		125		327
Short-term lease cost	37		26		91		53
Variable lease cost	704		195		984		245
Sublease income	(156)		(152)		(313)		(304)
Total	$	3,472	$	3,452	$	6,375	$	6,763

Balance sheet classifications at June 30, 2021 and December 31, 2020 are summarized below:


	June 30, 2021						December 31, 2020
(in thousands)	Right of use assets		Current right of use liabilities		Long-term right of use liabilities		Right of use assets		Current right of use liabilities		Long-term right of use liabilities
Operating Leases	$	43,037	$	7,576	$	43,217	$	40,586	$	8,562	$	38,296
Finance Leases	4,453		680		4,576		8,034		972		10,173
Total	$	47,490	$	8,256	$	47,793	$	48,620	$	9,534	$	48,469

Our future minimum lease payments as of June 30, 2021 under operating lease and finance leases, with initial or remaining lease terms in excess of one year, were as follows:


	June 30, 2021
(in thousands)	Operating Leases		Finance Leases
Years ending June 30:
2021	$	5,655	$	457
2022	9,215		906
2023	7,694		903
2024	6,690		828
2025	5,513		735
Thereafter	30,148		2,414
Total lease payments	64,915		6,243
Less: imputed interest	(14,122)		(987)
Present value of lease liabilities	$	50,793	$	5,256

Supplemental cash flow information related to our leases for the periods ending June 30, 2021 and June 30, 2020 were as follows:


(in thousands)	June 30, 2021		June 30, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash outflow from operating leases	$	5,521	$	6,533
Operating cash outflow from finance leases	$	125	$	280
Financing cash outflow (inflow) from finance leases	$	329	$	(76)

Weighted-average remaining lease terms and discount rate for our leases for the period ending June 30, 2021, were as follows:


	June 30, 2021
	Operating	Financing
Weighted-average remaining lease term (in years)	8.9	7.7
Weighted-average discount rate	5.63%	4.63%

(6) Inventories

Components of inventories at June 30, 2021 and December 31, 2020 are summarized as follows:


(in thousands)	June 30, 2021		December 31, 2020
Raw materials	$	29,124	$	23,762
Work in process	8,018		5,912
Finished goods and parts	65,819		86,993
Inventories	$	102,961	$	116,667

We record a reserve to the carrying value of our inventory to reflect the rapid technological change in our industry that impacts the market for our products. The inventory reserve was $20,113 and $20,125 as of June 30, 2021 and December 31, 2020, respectively.

At June 30, 2021, our obligation to repurchase inventory, included in accrued and other liabilities on our condensed consolidated balance sheets, was $308, relating to the sale of inventory to an assembly manufacturer and we had a commitment of $4,118 with the assembling manufacturer to purchase certain materials and supplies they acquired from third parties. At June 30, 2021, inventory held at assemblers was $3,115.

(7) Intangible Assets

Intangible assets, net, other than goodwill, at June 30, 2021 and December 31, 2020 are summarized as follows:


	June 30, 2021						December 31, 2020
(in thousands)	Gross (a)		Accumulated Amortization		Net		Gross (a)		Accumulated Amortization		Net		Weighted Average Useful Life Remaining (in years)
Intangible assets with finite lives:
Customer relationships	$	65,539	$	(54,771)	$	10,768	$	71,123	$	(56,682)	$	14,441	2.7
Acquired technology	42,018		(40,853)		1,165		42,472		(41,201)		1,271		5.8
Trade names	20,684		(16,599)		4,085		17,477		(16,506)		971		1.3
Patent costs	19,954		(11,415)		8,539		19,828		(10,999)		8,829		4.5
Trade secrets	19,838		(18,425)		1,413		20,188		(18,216)		1,972		1.7
Acquired patents	18,181		(15,848)		2,333		16,317		(15,723)		594		7.4
Other	18,609		(13,606)		5,003		19,793		(19,788)		5		6.0
Total intangible assets	$	204,823	$	(171,517)	$	33,306	$	207,198	$	(179,115)	$	28,083	4.6

a.Change in gross carrying amounts consists primarily of charges for license and patent costs, foreign currency translation, acquisitions and divestitures.

Amortization expense related to intangible assets was $2,502 and $4,929 for the quarter and six months ended June 30, 2021, respectively, compared to $4,144 and $8,546 for the quarter and six months ended June 30, 2020, respectively.

(8) Accrued and Other Liabilities

Accrued liabilities at June 30, 2021 and December 31, 2020 are summarized as follows:


(in thousands)	June 30, 2021		December 31, 2020
Compensation and benefits	$	30,796	$	24,629
Vendor accruals	12,841		18,762
Accrued taxes	10,455		14,952
Accrued other	1,889		6,138
Product warranty liability	3,160		2,348

Accrued professional fees	2,169		1,773
Royalties payable	1,258		1,210

Total	$	62,568	$	69,812

Other liabilities at June 30, 2021 and December 31, 2020 are summarized as follows:


(in thousands)	June 30, 2021		December 31, 2020
Long-term employee indemnity	$	10,478	$	12,228
Long-term tax liability	5,492		15,532
Defined benefit pension obligation	9,427		10,228
Long-term deferred revenue	5,576		6,163
Other long-term liabilities	1,685		7,096
Total	$	32,658	$	51,247

(9) Borrowings

Credit Facility

We have a 5-year $100,000 senior secured revolving credit facility (the “Senior Credit Facility”) to support working capital and general corporate purposes. The Senior Credit Facility also had a 5-year $100,000 senior secured term loan facility (the “Term Facility”) that, as discussed below, has been fully repaid and terminated. The Senior Credit Facility is guaranteed by certain of our subsidiaries. The guarantors guarantee, among other things, all our obligations and each other guarantor's obligations under the Senior Credit Facility. From time to time, we may be required to cause additional domestic subsidiaries to become guarantors under the Senior Credit Facility. The Senior Credit Facility is scheduled to mature on February 26, 2024, at which time all amounts outstanding thereunder will be due and payable. However, the maturity date of the Senior Credit Facility may be extended at our election with the consent of the lenders subject to the terms set forth in the Senior Credit Facility. The Senior Credit Facility contains customary covenants, some of which require us to maintain certain financial ratios that determine the amounts available and terms of borrowings and events of default. We were in compliance with all covenants at June 30, 2021.

The payment of dividends on our common stock is restricted under provisions of the Senior Credit Facility, which limits the amount of cash dividends that we may pay in any one fiscal year to $30,000. We currently do not pay, and have not paid, any dividends on our common stock, and we currently intend to retain any future earnings for use in our business.

Borrowings under the Senior Credit Facility are subject to interest at varying spreads above quoted market rates and a commitment fee is paid on the total unused commitment. Subject to certain terms and conditions contained in the Senior Credit Facility, we have the right to request up to four increases to the amount of the revolving facility in an aggregate amount not to exceed an additional $100,000.

We had a balance of $21,392 outstanding on the Term Facility at December 31, 2020. On January 1, 2021, the Company completed the sale of Cimatron, the subsidiary that operated the Company’s Cimatron integrated CAD/CAM software for tooling business and its GibbsCAM CNC programming software business. A portion of the proceeds from the sale were used to repay the outstanding balance on the Term Facility. The Term Facility is now fully repaid and terminated. Concurrent with the repayment of the Term Facility, we terminated the interest rate swap, resulting in a marked-to-market payment of $712. See Note 10 for additional information.

(10) Hedging Activities and Financial Instruments

Interest Rate Swap Contract

On July 8, 2019, we entered into a $50,000 interest rate swap contract, designated as a cash flow hedge, to minimize the risk associated with the variability of cash flows in interest payments from variable-rate debt due to fluctuations in the one-month USD-LIBOR, subject to a 0% floor, through February 26, 2024. Changes in the interest rate swap were expected to offset the changes in cash flows attributable to fluctuations of the one-month USD-LIBOR for the interest payments associated with our variable-rate debt.

On January 4, 2021, in connection with the repayment of the Term Facility, we terminated the interest rate swap agreement, which required a marked-to-market termination payment of $712 paid in January 2021. Amounts previously recognized in AOCL of $721 were released and reclassified into Interest and other income (expense), net on the accompanying condensed consolidated statements of operations and comprehensive income (loss) for the six months ended June 30, 2021.

The notional amount and fair value of the derivative on our balance sheet at December 31, 2020 was as follows:

(in thousands)

Balance Sheet location

Notional amount

Fair value

December 31, 2020

Interest rate swap contract

Other liabilities

15,000

(700)

Except as noted above, amounts released from AOCL and reclassified into Interest and other income (expense), net did not have a material impact on our condensed consolidated statements of operations and comprehensive income (loss) for the six months and quarters ended June 30, 2021 and 2020.

Foreign Currency Contracts

We conduct business in various countries using both the functional currencies of those countries and other currencies to effect cross border transactions. As a result, we are subject to the risk that fluctuations in foreign exchange rates between the dates that those transactions are entered into and their respective settlement dates will result in a foreign exchange gain or loss. When practicable, we endeavor to match assets and liabilities in the same currency on our balance sheet and those of our subsidiaries in order to reduce these risks. When appropriate, we enter into foreign currency contracts to hedge exposures arising from those transactions. We have elected not to prepare and maintain the documentation to qualify for hedge accounting treatment under ASC 815, “Derivatives and Hedging,” and therefore, all gains and losses (realized or unrealized) are recognized in Interest and other expense, net in the condensed consolidated statements of operations and comprehensive income (loss). Depending on their fair value at the end of the reporting period, derivatives are recorded either in prepaid expenses and other current assets or in accrued liabilities on the condensed consolidated balance sheets.

We had $78,826 and $101,781 in notional foreign exchange contracts outstanding as of June 30, 2021 and December 31, 2020, respectively. The fair values of these contracts were not material.

We translate foreign currency balance sheets from each international businesses’ functional currency (generally the respective local currency) to U.S. dollars at end-of-period exchange rates, and statements of earnings at average exchange rates for each period. The resulting foreign currency translation adjustments are a component of other comprehensive income (loss). We do not hedge the fluctuation in reported revenue and earnings resulting from the translation of these international operations' results into U.S. dollars.

(11) Net Income (Loss) Per Share

Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the applicable period. Diluted net income (loss) per share incorporates the additional shares issuable upon assumed exercise of stock options and the release of restricted stock and restricted stock units, except in such case when their inclusion would be anti-dilutive.


	Quarter Ended June 30,				Six Months Ended June 30,
(in thousands, except per share amounts)	2021		2020		2021		2020
Numerator:
Net income (loss)	$	(9,632)	$	(37,951)	$	35,596	$	(56,875)
Denominator:
Weighted average shares - basic	122,147		115,503		121,931		115,047
Dilutive securities	—		—		3,138		—
Weighted average shares - diluted	122,147		115,503		125,069		115,047

Net income (loss) per share - basic	$	(0.08)	$	(0.33)	$	0.29	$	(0.49)
Net income (loss) per share - diluted	$	(0.08)	$	(0.33)	$	0.28	$	(0.49)

For the quarters ended June 30, 2021 and 2020, and six months ended June 30, 2020, the effect of dilutive securities, including non-vested stock options and restricted stock awards/units, was excluded from the denominator for the calculation of diluted net loss per share because we recognized a net loss for the periods and their inclusion would be anti-dilutive. Dilutive securities excluded for the quarters ended June 30, 2021 and 2020 were 4.3 million and 6.6 million, respectively, and for the six months ended June 30, 2020 were 6.6 million. For the six months ended June 30, 2021 dilutive securities excluded were 0.4 million.

On August 5, 2020, we entered into an Equity Distribution Agreement for an At-The-Market equity offering program (“ATM Program”) under which we could have issued and sold, from time to time, shares of our common stock. On January 6, 2021, following the closing of the sale of Cimatron and the receipt of the related purchase price proceeds, the Company terminated the ATM Program. No shares of our stock were issued under the ATM Program in 2021.

(12) Fair Value Measurements

Fair value is the exchange price to sell an asset or transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. Fair value measurements use market data or assumptions market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs may be readily observable, corroborated by market data, or generally unobservable. Valuation techniques maximize the use of observable inputs and minimize use of unobservable inputs.

Cash equivalents, Israeli severance funds and derivatives are valued utilizing the market approach to measure fair value for financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

Assets and liabilities measured at fair value on a recurring basis are summarized below:


	Fair Value Measurements as of June 30, 2021
(in thousands)	Level 1		Level 2		Total
Description
Cash equivalents (a)	$	42,470	$	—	$	42,470
Israeli severance funds (b)	$	—	$	6,606	$	6,606


	Fair Value Measurements as of December 31, 2020
(in thousands)	Level 1		Level 2		Total
Description
Cash equivalents (a)	$	199	$	—	$	199
Israeli severance funds (b)	$	—	$	6,422	$	6,422
Derivative financial instruments (c)	$	—	$	(700)	$	(700)

a.Cash equivalents include funds held in money market instruments and are reported at their current carrying value, which approximates fair value due to the short-term nature of these instruments and are included in cash and cash equivalents in the condensed consolidated balance sheet.

b.We partially fund a liability for our Israeli severance requirement through monthly deposits into fund accounts, the value of these contributions is recorded to non-current assets on the condensed consolidated balance sheet.

c.Derivative instruments are reported based on published market prices for similar assets or are estimated based on published market prices for similar assets or are estimated based on observable inputs such as interest rates, yield curves, credit risks, spot and future commodity prices and spot and future exchange rates. See Note 10 for additional information on our derivative financial instruments.

We did not have any transfers of assets and liabilities between Level 1, Level 2 and Level 3 of the fair value measurement hierarchy during the six months ended June 30, 2021.

(13) Income Taxes

We maintain the exception under ASC 740-270-30-36(b), "Accounting for Income Taxes", for jurisdictions that do not have reliable estimates of ordinary income due to the volatility in the industry. Based on the continued global financial uncertainty due to the COVID-19 pandemic and volatility in the industry, we have continued to use a year-to-date methodology in determining the effective tax rate for the quarter and six months ended June 30, 2021.

For the quarter and six months ended June 30, 2021, the Company's effective tax rate was 7.2% and (34.2)%, respectively. For the quarter and six months ended June 30, 2020, the Company's effective tax rate was (4.0)% and 0.7%, respectively. The difference between the statutory tax rate and the effective tax rate for the quarter and six months ended June 30, 2021 is primarily driven by the reduction of a liability for uncertain tax positions, which includes the release noted in the paragraph below, and the presence of valuation allowances in various jurisdictions. The difference between the statutory tax rate and the effective tax rate for the quarter and six months ended June 30, 2020 is primarily driven by valuation allowances in various jurisdictions, the foreign rate differential between the U.S. tax rate and the foreign tax rates, and the change in U.S. tax law allowing for the carryback of certain U.S. net operating losses (“NOLs”) as explained in the paragraph below.

In response to the global pandemic resulting from COVID-19, the U.S. government enacted tax legislation on March 27, 2020 under the Coronavirus Aid Relief, and Economic Security Act ("CARES Act"). This legislation allowed us to carryback NOLs generated in the 2018 and 2019 tax years up to five years. A tax receivable was recorded during the first quarter of 2020 for the anticipated carryback in the amount of $8,900, along with associated uncertain tax positions of $5,700. During the fourth quarter of 2020, additional uncertain tax positions of $3,200 were recorded to fully reserve the $8,900 related to the carryback. During the first quarter of 2021, the Company received two favorable private letter rulings triggering release of the uncertain tax positions for $8,900. As of the close of the quarter ended June 30, 2021, approximately $2,500 of the $8,900 refund has been received by the Company thus far. The remaining refund of $6,400 was received by the Company on July 29, 2021.

(14) Commitments and Contingencies

We have an inventory purchase commitment with an assembling manufacturer. See Note 6 for additional information regarding this inventory purchase commitment.

Litigation

Export Controls and Government Contracts Compliance Matter

In October 2017, we received an administrative subpoena from the Bureau of Industry and Security of the Department of Commerce (“BIS”) requesting the production of records in connection with possible violations of U.S. export control laws, including with regard to our Quickparts.com, Inc. subsidiary. In addition, while collecting information responsive to the above-referenced subpoena, our internal investigation identified potential violations of the International Traffic in Arms Regulations administered by the Directorate of Defense Trade Controls of the Department of State (“DDTC”) and potential violations of the Export Administration Regulations administered by the BIS. On June 8, 2018 and thereafter, we submitted voluntary disclosures to BIS and DDTC identifying numerous potentially unauthorized exports of technical data.

As part of our ongoing review of trade compliance risks and our cooperation with the government, on November 20, 2019, we submitted to the U.S. Treasury Department’s Office of Foreign Assets Control (“OFAC”) an initial notice of voluntary disclosure regarding potential violations of economic sanctions related to Iran. We continued to investigate this issue and filed a final disclosure with OFAC on May 20, 2020. We have and will continue to implement compliance enhancements to our export controls, trade sanctions, and government contracting compliance program to address the issues identified through our ongoing internal investigation and will cooperate with DDTC and BIS, as well as the U.S. Departments of Justice, Defense, Homeland Security and Treasury in their ongoing reviews of these matters. In connection with these ongoing reviews, in August 2020, the Company received two federal grand jury subpoenas issued by the U.S. District Court for the Northern District of Texas. The Company responded to these two subpoenas and will continue to fully cooperate with the U.S. Department of Justice in the related investigation.

In addition, on July 19, 2019, we received a notice of immediate suspension of federal contracting from the United States Air Force, pending the outcome of an ongoing investigation. The suspension applied to 3D Systems, its subsidiaries and affiliates, and was related to the potential export controls violations involving our On-Demand manufacturing business described above. Under the suspension, we were generally prohibited from receiving new federal government contracts or subcontracts from any executive branch agency as described in the provisions of 48 C.F.R Subpart 9.4 of the Federal Acquisition Regulation. The suspension allowed us to continue to perform current federal contracts, and also to receive awards of new subcontracts for items under $35 and for items considered commercially available off-the-shelf items. The Air Force lifted the suspension on September 6, 2019 following the execution of a two-year Administrative Agreement with us. We are now eligible to obtain and perform U.S. government contracts and subcontracts without restrictions. Under the Administrative Agreement, we will be monitored and evaluated by independent monitors who will report to the Air Force on our compliance with the terms of the Company’s Ethics & Compliance Program, including its overall culture, government contracting compliance program, and export controls compliance program.

Although we cannot predict the ultimate resolution of these matters, we have incurred and expect to continue to incur significant legal costs and other expenses in connection with responding to the U.S. government agencies.

Shareholder Suits

The Company and certain of its current and former executive officers have been named as defendants in a consolidated putative stockholder class action lawsuit pending in the United States District Court for the Eastern District of New York. The action is styled In re 3D Systems Securities Litigation, No. 1:21-cv-01920-NGG-TAM (E.D.N.Y.). The original Complaint, which was filed on April 9, 2021, alleges that defendants violated the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions, and that the current and former executive officers named as defendants are control persons under Section 20(a) of the Exchange Act. The original Complaint was filed on behalf of stockholders who purchased shares of the Company’s common stock between May 6, 2020 and March 1, 2021, and seeks monetary damages on behalf of the purported class. On July 14, 2021, the Court appointed a Lead Plaintiff for the putative class and approved his choice of Lead Counsel. The deadline for Lead Plaintiff to file his Consolidated Amended Complaint is September 13, 2021, and the deadline for defendants to move, answer, or otherwise respond is November 12, 2021.

The Company has been named as a nominal defendant and certain of its current and former executive officers have been named as defendants in derivative lawsuits pending in the United States District Court for the Eastern District of New York and the South Carolina Court of Common Pleas for the 16th Circuit, York County. The actions are styled Nguyen v. Joshi, et al., No. 21-cv-03389-DG-CLP (E.D.N.Y.) (the “New York Derivative Action”), Lesar v. Graves, et al., No. 2021CP4602308 (S.C., Ct. of Common Pleas for the 16th Judicial Cir., Cty. of York) (the “Lesar Action”), and Scanlon v. Graves, et al., No. 2021CP4602312 (S.C., Ct. of Common Pleas for the 16th Judicial Cir., Cty. of York) (together with the Lesar Action, the “South Carolina Derivative Actions”). The Complaint in the New York Derivative Action, which was filed on June 15, 2021, asserts breach of fiduciary duty claims against all defendants and claims for contribution under the federal securities laws against certain of the defendants. The Complaints in the South Carolina Derivative Actions, which were filed on July 26, 2021, assert breach of fiduciary duty and unjust enrichment claims against defendants.

The Company believes the claims alleged in the putative securities class action and derivative lawsuits are without merit and the Company intends to defend itself and its current and former officers vigorously.

Other

We are involved in various other legal matters incidental to our business. Although we cannot predict the results of the litigation with certainty, we believe that the disposition of all these various other legal matters will not have a material adverse effect, individually or in the aggregate, on our consolidated results of operations, consolidated cash flows or consolidated financial position.

(15) Restructuring and Exit Activity Costs

On August 5, 2020, we announced, in connection with the new strategic focus new and organizational realignment, a restructuring plan intended to align our operating costs with current revenue levels and better position the Company for future sustainable and profitable growth. The restructuring plan included a reduction of nearly 20% of our workforce, with the majority of the workforce reduction completed by December 31, 2020. We completed the restructuring efforts in the second quarter of 2021. Cost reduction efforts included reducing the number of facilities and examining every aspect of our manufacturing and operating costs. We incurred cash charges for severance, facility closing and other costs, primarily in the second half of 2020, and continued to incur additional charges through the second quarter of 2021, when we finalized all the actions to be taken. Non-cash charges related to these actions were $6,400 and are included in facility closing costs. We also divested parts of the business that do not align with this strategic focus. See Note 2.

In connection with the restructuring plan, we recorded pre-tax costs during the six months ended June 30, 2021, included within Selling, general and administrative in the condensed consolidated income statement, and incurred total costs as follows:


(in thousands)	Costs Incurred during 2020		Costs Incurred during the six months ended June 30, 2021		Total Costs Incurred
Severance, termination benefits and other employee costs	$	12,914	$	660	$	13,574
Facility closing costs	6,470		640		7,110
Other costs	668		(179)		489
Total	$	20,052	$	1,121	$	21,173

The liabilities at June 30, 2021 related to these costs were principally recorded in accrued expenses in the condensed consolidated balance sheets and were as follows:


(in thousands)	Liability at December 31, 2020		Costs Incurred during 2021		Costs Paid During 2021		Non-cash adjustments		Liability at June 30, 2021
Severance, termination benefits and other employee costs	$	7,173	$	660	$	(7,768)	$	—	$	65
Facility closing costs	—		640		(640)		—		—
Other costs	—		(179)				611		432
Total	$	7,173	$	1,121	$	(8,408)	$	611	$	497

(16) Subsequent Events

We have evaluated subsequent events through the date these financial statements were issued and determined the items below:

On July 28, 2021, the Company entered into a definitive agreement to sell its medical simulation business, Simbionix, to Surgical Science Sweden AB, for a purchase price of $305,000, subject to customary closing conditions and adjustments. The transaction is expected to be completed in August 2021.

As discussed in Note 13, on July 29, 2021 we received the remaining $6,400 refund from the IRS related to our CARES Act NOL carryback claim.

On July 9, 2021 we signed a ten year build to suit lease in Littleton, CO for approximately 50,000 rentable square feet. Total rent over the ten year lease is approximately $14,500. The lease will commence when construction is substantially complete.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read together with the unaudited condensed consolidated financial statements and the notes thereto included in Item 1 (the “Financial Statements”) of this Quarterly Report on Form 10-Q (“Form 10-Q”). Also, we are subject to a number of risks and uncertainties that may affect our future performance that are discussed in greater detail in the sections entitled “Forward-Looking Statements” at the end of this Item 2 and that are discussed or referred to in Item 1A of Part II of this Form 10-Q.

Business Overview

3D Systems Corporation (“3D Systems” or the “Company” or “we” or “us”) markets our products and services through subsidiaries in North America and South America (collectively referred to as “Americas”), Europe and the Middle East (collectively referred to as “EMEA”) and the Asia Pacific region (“APAC”). We provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, on-demand manufacturing services and digital design tools. Our solutions support advanced applications in two key industry verticals: Healthcare (which includes dental, medical devices and personalized health services) and Industrial (which includes aerospace, defense, transportation and general manufacturing). We have over 30 years of experience and expertise which have proven vital to our development of an ecosystem and end-to-end digital workflow solutions which enable customers to optimize product designs, transform workflows, bring innovative products to market and drive new business models.

As of January 1, 2021, we determined the Company has two reportable segments, Healthcare and Industrial, whereas the Company previously only reported its consolidated results in one reportable segment. Prior year Healthcare and Industrial revenue amounts discussed herein have been recast to conform with current year presentation.

New Strategic Focus and Restructuring

Our business portfolio is well-balanced across end markets and geographies and includes a high degree of businesses serving critical sectors such as healthcare, aerospace and durable goods. In May 2020, a new Chief Executive Officer and President, Dr. Jeffrey Graves, was hired. Dr. Graves undertook an initial assessment of the Company and on August 5, 2020, we announced a strategic focus and reorganization and, to align our cost structure to the level of revenues, a restructuring plan was also announced. We completed the restructuring efforts in the second quarter of 2021. Cost reduction efforts include reducing the number of facilities and examining every aspect of our manufacturing and operating costs. We incurred cash charges for severance, facility closing and other costs, primarily in the second half of 2020, and continued to incur additional charges through the second quarter of 2021, when we finalized all the actions to be taken. We incurred total charges of $21.1 million for severance, facility closings and other costs in accomplishing these efforts, including non-cash charges of $6.4 million which are included in facility closing costs. We also divested and are divesting parts of the business that do not align with this strategic focus. See Note 15 for additional discussion.

COVID-19 Pandemic Response

As we continue to closely monitor the global impact of the COVID-19 pandemic, our top priority remains the health and safety of our employees and their families and communities. Our Crisis Response Steering Committee regularly reviews and adapts our protocols based on evolving research and guidance related to the virus. While operations continue, we continue to restrict travel and meetings, publish pertinent information, and adapt to a world where many in our workforce are remote and those coming on-site are following new safety measures. In certain of our locations, where local conditions and regulations allow, our employees have begun to return to working on-site. We continue to watch conditions and regulations and remain committed to protecting our employees, delivering for our customers and supporting our communities.

Looking Forward

Our operations in Americas, EMEA and APAC expose us to risks associated with public health crises and epidemics/pandemics, such as the COVID-19 pandemic. While the COVID-19 pandemic continued to impact our reported results for the quarter ended June 30, 2021, we are unable to predict the longer-term impact that the pandemic may have on our business, results of operations, financial position or cash flows. The extent to which our operations may be impacted by the dynamic nature of the COVID-19 pandemic will depend largely on future developments, which are highly uncertain and cannot be accurately predicted, including the severity or resurgence of the outbreak and actions by government authorities to contain the outbreak or treat its impact. Furthermore, the impacts of a potential worsening of global economic conditions, further supply chain disruptions, including shortages of critical components, and the continued disruptions to, and volatility in, the financial markets remain unknown.

Summary of Second Quarter 2021 Financial Results

Total consolidated revenue for the second quarter of 2021 increased 44.1% compared to the same period last year, driven by a strong performance in both our Healthcare and Industrial segments. Revenue from Healthcare increased 68.6% to $82.8 million, compared to the same period last year, as sales in both medical and dental applications recovered from the lows of the pandemic. Industrial sales increased 25.3% to $79.7 million, compared to the same period last year, primarily due to the continued recovery from the economic slowdown due to the pandemic.

Gross profit for the quarter ended June 30, 2021 increased by 96.2%, or $33.8 million, to $69.0 million, compared to $35.2 million for the quarter ended June 30, 2020. Gross profit margin for the quarters ended June 30, 2021 and June 30, 2020 was 42.4% and 31.2%, respectively. The increase in gross profit was primarily due to higher revenue in the quarter ended June 30, 2021 and the negative impact of an end-of-life inventory charge recorded in the quarter ended June 30, 2020.

Operating expenses for the quarter ended June 30, 2021 increased by 14.5%, or $10.0 million, to $79.1 million, compared to $69.0 million for the quarter ended June 30, 2020. Selling, general and administrative expenses for the quarter ended June 30, 2021 increased by 18.1%, or $9.4 million, to $61.5 million, compared to $52.0 million for the quarter ended June 30, 2020. Research and development expenses for the quarter ended June 30, 2021 increased by 3.6%, or $0.6 million, to $17.6 million, compared to $17.0 million for the quarter ended June 30, 2020. Our higher operating expenses reflect increased spending as business activity increased as compared to the same period last year, as well as higher stock-based and bonus compensation expenses reflecting better than expected operating performance, partially offset by benefits from cost restructuring.

Our operating loss for the quarter ended June 30, 2021 was $10.1 million, compared to $33.9 million for the quarter ended June 30, 2020. The lower loss was driven by higher revenue, benefits from cost restructuring, and improved gross margins as discussed above discussed.

For the six months ended June 30, 2021, we generated $42.0 million of cash from operations, primarily driven by the increase in operating income and better working capital management. For the six months ended June 30, 2020, we used $21.0 million of cash from operations. Our unrestricted cash balance at June 30, 2021 and December 31, 2020, was $131.8 million and $75.0 million, respectively. The higher cash balance resulted from $54.7 million in net proceeds from the Cimatron sale and $42.0 million from operations, partially offset by $21.4 million for repayments of debt, $4.0 million for payments related to a prior acquisition, $10.9 million for current acquisitions, $6.6 million related to share settlement of stock-based compensation, and $8.2 million for capital expenditures.

Results of Operations

Revenue

Current year revenue has improved as the prior year was negatively impacted by the effects of the COVID-19 pandemic, most severely toward the end of the first quarter 2020 and into the second quarter 2020, as many of our customers were shut down or on a significantly reduced level of activity. Additionally, given the relatively high price of certain 3D printers and a corresponding lengthy selling cycle as well as relatively low unit volume of the higher priced printers in any particular period, a shift in the timing and concentration of orders and shipments from one period to another can materially affect reported revenue in any given period.

In addition to changes in sales volumes, there are two other primary drivers of changes in revenue from one period to another: (1) the combined effect of changes in product mix and average selling prices and (2) the impact of fluctuations in foreign currencies. As used in this Management’s Discussion and Analysis, the price and mix effects relate to changes in revenue that are not able to be specifically related to changes in unit volume.

We earn revenue from the sale of products and services through our Healthcare and Industrial segments. The products category includes 3D printers and corresponding materials, healthcare simulators and digitizers, software licenses, 3D scanners and haptic devices. The majority of materials used in our 3D printers are proprietary. The services category includes maintenance contracts and services on 3D printers and simulators, software maintenance, on-demand solutions and healthcare services.

The following tables set forth the change in revenue for the quarters and six months ended June 30, 2021 and 2020.

Table 1


(Dollars in thousands)	Products				Services				Total
Revenue — second quarter 2020	$	62,213			$	50,564			$	112,777
Change in revenue:
Volume	20,281		32.6	%	1,564		3.1	%	21,845		19.4	%
Price/Mix	20,696		33.3	%	33		0.1	%	20,729		18.4	%
Foreign currency translation	5,448		8.8	%	1,758		3.5	%	7,206		6.4	%
Net change	46,425		74.6	%	3,355		6.6	%	49,780		44.1	%
Revenue — second quarter 2021	$	108,638			$	53,919			$	162,557

Total consolidated revenue for the second quarter of 2021 compared to the same period last year increased 44.1%, primarily due to higher volume from the continued rebound from adverse impacts of COVID-19 in the prior year, and favorable price/mix and foreign currency impact partially offset by divestitures. Recurring revenue, which includes service and materials, was $106.2 million and $79.2 million for the quarters ended June 30, 2021 and 2020, respectively.

For the quarters ended June 30, 2021 and 2020, products revenue from Healthcare contributed $57.8 million and $29.9 million, respectively, and products revenue from Industrial contributed $50.8 million and $32.3 million, respectively. The higher products revenue in Healthcare was due to continued strength in the dental market and higher products revenue in Industrial was primarily due to higher volumes, favorable price/mix and foreign currency impact partially offset by divestitures.

For the quarters ended June 30, 2021 and 2020, services revenue from Healthcare contributed $25.0 million and $19.3 million, respectively, and services revenue from Industrial contributed $28.9 million and $31.3 million, respectively. The higher services revenue in Healthcare was due to strong sales in both dental and medical applications; whereas, lower services revenue in Industrial was due to divestitures.

For the quarters ended June 30, 2021 and 2020, revenue from operations outside the U.S. was 43.9% and 51.0% of total revenue, respectively.

Table 2


(Dollars in thousands)	Products				Services				Total
Revenue — six months 2020	$	141,952			$	106,460			$	248,412
Change in revenue:
Volume	31,064		21.9	%	(3,691)		(3.5)	%	27,373		11.0	%
Price/Mix	22,845		16.1	%	33		—	%	22,878		9.2	%
Foreign currency translation	6,425		4.5	%	3,585		3.4	%	10,010		4.0	%
Net change	60,334		42.5	%	(73)		(0.1)	%	60,261		24.3	%
Revenue — six months 2021	$	202,286			$	106,387			$	308,673

Total consolidated revenue increased 24.3% for the six months ended June 30, 2021 compared to the same period last year, primarily due to increased volume from the continued rebound from the adverse impacts of COVID-19 in the prior year and favorable price/mix and foreign currency impact. Recurring revenue, which includes service and materials, was $202.9 million and $176.5 million for the six months ended June 30, 2021 and 2020, respectively.

For the six months ended June 30, 2021 and 2020, products revenue from Healthcare contributed $107.4 million and $62.0 million, respectively, and products revenue from Industrial contributed $94.9 million and $79.9 million, respectively. The higher products revenue in Healthcare was due to continued strength in the dental market and higher products revenue in Industrial was primarily due to higher volumes, favorable price/mix and foreign currency impact partially offset by divestitures.

Services revenue was flat primarily due to decrease in volumes, which were offset by favorable impact of foreign currency translation. For the six months ended June 30, 2021 and 2020, services revenue from Healthcare contributed $47.9 million and $39.4 million, respectively, and services revenue from Industrial contributed $58.5 million and $67.1 million, respectively. The higher services revenue in Healthcare was due to strong sales in both dental and medical applications; whereas, the lower services revenue in Industrial was due to lower on-demand volume and divestitures.

Gross profit and gross profit margins

The following tables set forth gross profit and gross profit margins for the quarters and six months ended June 30, 2021 and 2020.

Table 3


	Quarter Ended June 30,
	2021				2020				Change in Gross Profit				Change in Gross Profit Margin
(Dollars in thousands)	Gross Profit		Gross Profit Margin		Gross Profit		Gross Profit Margin		$		%		Percentage Points	%
Products	$	46,003	42.3	%	$	10,929	17.6	%	$	35,074	320.9	%	24.7	140.3	%
Services	23,002		42.7	%	24,238		47.9	%	(1,236)		(5.1)	%	(5.2)	(10.9)	%
Total	$	69,005	42.4	%	$	35,167	31.2	%	$	33,838	96.2	%	11.2	35.9	%

For the quarter ended June 30, 2021, as compared to the same period last year, the increase in total consolidated gross profit was predominantly due to the higher sales volume as previously discussed, and the end of life inventory charge recorded in the quarter ended June 30, 2020, partially offset by divestitures. Products gross profit increased primarily due to higher sales volume as well as an improved gross profit margin due to the significantly improved capacity utilization and the end of life inventory charge recorded in the quarter ended June 30, 2020. Services gross profit decreased primarily due to lower on-demand volume and divestitures.

Table 4


	Six Months Ended June 30,
	2021				2020				Change in Gross Profit				Change in Gross Profit Margin
(Dollars in thousands)	Gross Profit		Gross Profit Margin		Gross Profit		Gross Profit Margin		$		%		Percentage Points	%
Products	$	86,287	42.7	%	$	42,214	29.7	%	$	44,073	104.4	%	13.0	43.8	%
Services	46,958		44.1	%	50,085		47.0	%	(3,127)		(6.2)	%	(2.9)	(6.2)	%
Total	$	133,245	43.2	%	$	92,299	37.2	%	$	40,946	44.4	%	6.0	16.1	%

For the six months ended June 30, 2021, compared to the same period last year, the increase in total consolidated gross profit was predominantly due to the higher sales volume as previously discussed, partially offset by divestitures and the end of life inventory charge recorded in the quarter ended June 30, 2020. Products gross profit increased primarily due to higher sales volume as well as an improved gross profit margin due to significantly improved capacity utilization and the end of life inventory charge recorded in the six months ended June 30, 2020. Services gross profit decreased primarily due to lower on-demand volume and divestitures.

Operating expenses

The following tables set forth the components of operating expenses for the quarters and six months ended June 30, 2021 and 2020.

Table 5


	Quarter Ended June 30,
	2021				2020				Change
(Dollars in thousands)	Amount		% Revenue		Amount		% Revenue		$		%
Selling, general and administrative expenses	$	61,463	37.8	%	$	52,042	46.1	%	$	9,421	18.1	%
Research and development expenses	17,602		10.8	%	16,997		15.1	%	605		3.6	%

Total operating expenses	$	79,065	48.6	%	$	69,039	61.2	%	$	10,026	14.5	%

For the quarter ended June 30, 2021, as compared to the same period last year, selling, general and administrative expenses increased predominantly due to higher stock-based compensation and bonus expense reflecting better than expected operating performance as well as increased marketing expense, partially offset by the realization of cost savings from the prior year restructuring program and divestitures. See Note 15 for additional discussion regarding restructuring.

For the quarter ended June 30, 2021, as compared to the same period last year, research and development expenses increased due to an increase in collaboration expenses partially offset by the cost savings from the prior year restructuring program and divestitures.

Table 6


	Six Months Ended June 30,
	2021				2020				Change
(Dollars in thousands)	Amount		% Revenue		Amount		% Revenue		$		%
Selling, general and administrative expenses	$	111,063	36.0	%	$	108,148	43.5	%	$	2,915	2.7	%
Research and development expenses	34,201		11.1	%	36,241		14.6	%	(2,040)		(5.6)	%
Total operating expenses	$	145,264	47.1	%	$	144,389	58.1	%	$	875	0.6	%

For the six months ended June 30, 2021, compared to the same period last year, selling, general and administrative expenses increased primarily due to higher stock-based compensation and bonus expense reflecting better than expected operating performance as well as increased marketing expense, partially offset by the realization of cost savings from the prior year restructuring program and divestitures. See Note 15 for additional discussion regarding restructuring.

For the six months ended June 30, 2021, compared to the same period last year, research and development expenses decreased due to the realization of cost savings from the prior year restructuring program and divestitures.

Loss from operations

The following table sets forth loss from operations for the quarters and six months ended June 30, 2021 and 2020.

Table 7


	Quarter Ended June 30,				Six Months Ended June 30,
(Dollars in thousands)	2021		2020		2021		2020




Loss from operations:	$	(10,060)	$	(33,872)	$	(12,019)	$	(52,090)

The decrease in loss from operations for the quarter and six months ended June 30, 2021, as compared to the prior year periods, was primarily driven by an increase in revenue and improved gross profit margin, partial offset by an increase in operating expenses, as previously discussed.

See “Revenue,” “Gross profit and gross profit margins” and “Operating expenses” above.

Interest and other income (expense), net

The following table sets forth the components of interest and other income (expense), net, for the quarters and six months ended June 30, 2021 and 2020.

Table 8


	Quarter Ended June 30,				Six Months Ended June 30,
(Dollars in thousands)	2021		2020		2021		2020
Interest and other income (expense), net
Foreign exchange gain (loss)	$	(72)	$	(871)	$	2,057	$	(983)
Interest expense, net	(211)		(2,050)		(1,249)		(3,088)
Other income (expense), net	(33)		306		37,729		(1,108)
Total interest and other income (expense), net	$	(316)	$	(2,615)	$	38,537	$	(5,179)

Interest expense, net, decreased for the six months and quarter ended June 30, 2021, as compared to the prior year periods primarily due to lower interest expense related to the repayment of the 5-year $100 million senior secured term loan facility (the "Term Facility") in the first quarter of 2021 and interest income related to cash proceeds from the Cimatron sale. The year over year benefits for the six months ended June 30, 2021 were partially offset by the realization of losses previously recognized in Accumulated other comprehensive resulting from the termination of the interest rate swap in first quarter of 2021.

Foreign exchange gain (loss), net, for the six months and quarter ended June 30, 2021, as compared to the prior year periods, improved due to the favorable movements in the EUR/USD and GBP/USD exchanges rates.

Other income (expense), net, for the six months ended June 30, 2021 as compared to the six months ended June 30, 2020, increased primarily due to the $32.9 million gain on sale of Cimatron and a $6.5 million favorable foreign exchange gain related to the Cimatron sale.

Net income (loss)

The following tables set forth the primary components of net income (loss) for the quarters and six months ended June 30, 2021 and 2020.

Table 9


	Quarter Ended June 30,
(Dollars in thousands, except per share amounts)	2021		2020		Change
Loss from operations	$	(10,060)	$	(33,872)	$	23,812
Other non-operating items:
Interest and other income (expense), net	(316)		(2,615)		2,299
Benefit (provision) for income taxes	744		(1,464)		2,208
Net loss	$	(9,632)	$	(37,951)	$	28,319



Weighted average shares - basic	122,147		115,503
Weighted average shares - diluted	122,147		115,503

Net loss per share - basic	$	(0.08)	$	(0.33)
Net income loss per share - diluted	$	(0.08)	$	(0.33)

The decrease in net loss for the quarter ended June 30, 2021, as compared to the prior year period, was primarily driven by a decrease in loss from operations, as previously discussed.

Table 10


	Six Months Ended June 30,
(Dollars in thousands)	2021		2020		Change
Loss from operations	$	(12,019)	$	(52,090)	$	40,071
Other non-operating items:
Interest and other income (expense), net	38,537		(5,179)		43,716
Benefit for income taxes	9,078		394		8,684
Net income (loss)	$	35,596	$	(56,875)	$	92,471

Weighted average shares - basic	121,931		115,047
Weighted average shares - diluted	125,069		115,047

Net income (loss) per share - basic	$	0.29	$	(0.49)
Net income (loss) per share - diluted	$	0.28	$	(0.49)

The net income for the six months ended June 30, 2021, as compared to the net loss from the prior year period, is primarily due to the decrease in the loss from operations and the gain on the sale of Cimatron both as previously discussed.

Liquidity and Capital Resources

We assess our liquidity in terms of our ability to generate cash to fund our operating, investing and financing activities. In doing so, we review and analyze our current cash on hand, the number of days our sales are outstanding, inventory turns, capital expenditure commitments and accounts payable turns. Our cash requirements primarily consist of funding working capital and capital expenditures.

At June 30, 2021, we had cash on hand of $132.5 million, including restricted cash, and no outstanding debt. We also had a $100 million unused revolving credit facility with full availability, based on the terms of the agreement. Cash on hand, including restricted cash and cash classified as held for sale, increased $47.8 million since December 31, 2020. The higher cash balance resulted from proceeds of $54.7 million from the Cimatron sale and $42.0 million from operations, partially off by $21.4 million for repayments of debt, $4.0 million payments related to a prior acquisition, $10.9 million for current acquisitions, $6.6 million related to net settlement of stock-based compensation, and $8.2 million for capital expenditures. Cash from operations was impacted by withholding taxes of $6.6 million related to the Cimatron divestiture.

On January 1, 2021, the Company completed the sale of 100% of the issued and outstanding equity interests of Cimatron, the subsidiary that operated the Company’s Cimatron integrated CAD/CAM software for tooling business and its GibbsCAM CNC programming software business, for approximately $64.2 million, after certain adjustments and excluding $9.5 million of cash amounts transferred to the purchaser.

We expect that cash flow from operations, cash and cash equivalents, and other sources of liquidity such as cash proceeds from announced but not closed divestitures, bank credit facilities and issuing equity or debt securities, will be available and sufficient to meet all foreseeable cash requirements.

Cash held outside the U.S. at June 30, 2021 was $57.3 million, or 43.4% of total cash and cash equivalents, compared to $49.7 million, or 66.2% of total cash and cash equivalents, at December 31, 2020. As our previously unremitted earnings have been subjected to U.S. federal income tax, we expect any repatriation of these earnings to the U.S. would not incur significant federal and state taxes. However, these dividends are subject to foreign withholding taxes that are estimated to result in the Company incurring tax costs in excess of the cost to obtain cash through other means. Cash equivalents are comprised of funds held in money market instruments and are reported at their current carrying value, which approximates fair value due to the short term nature of these instruments. We strive to minimize our credit risk by investing primarily in investment grade, liquid instruments and limit exposure to any one issuer depending upon credit quality. See “Cash flow” discussion below.

Cash flow

Cash flow from operations

Cash provided by operating activities for the six months ended June 30, 2021 was $42.0 million, while cash used in operating activities for the six months ended June 30, 2020 was $21.0 million.

Working capital provided cash of $0.4 million for the six months ended June 30, 2021 and used cash of $19.1 million for the six months ended June 30, 2020. For the six months ended June 30, 2021, drivers of working capital related to cash inflows were a decrease in accounts receivable and inventory and an increase in accounts payable, partially offset by an increase in prepaid expenses and other current assets and a decrease in deferred revenue, and accrued and other liabilities, driven by withholding tax payments related to the Cimatron sale. For the six months ended June 30, 2020, drivers of working capital related to cash outflows were an increase in inventory and prepaid expenses, partially offset by an decrease in accounts receivable and an increase in accounts payable, deferred revenue and other accrued liabilities.

Cash flow from investing activities

For the six months ended June 30, 2021, the primary inflows of cash related to proceeds from the sale of Cimatron, partially offset by capital expenditures and payments related to current acquisitions and a prior acquisition. For the six months ended June 30, 2020, the primary outflows of cash related to the purchases of noncontrolling interest and capital expenditures. Capital expenditures were $8.2 million and $7.2 million for the six months ended June 30, 2021 and 2020, respectively.

Cash flow from financing activities

Cash used in financing activities was $28.4 million for the six months ended June 30, 2021, and $27.3 million for the six months ended June 30, 2020. The primary outflow of cash for the six months ended June 30, 2021 related to repayment of the Term Facility and settlements of stock-based compensation. The primary outflow of cash for the six months ended June 30, 2020 related to partial repayment of the Term Facility and settlements of stock-based compensation.

Recent Accounting Pronouncements

Refer to Note 1 - Basis of Presentation of the Notes to Financial Statements (Part I, Item 1 of this Form 10-Q) for further discussion.

Critical Accounting Policies and Significant Estimates

Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, costs and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.

As of the date of this report, there have been no changes to our critical accounting policies and estimates described in the Annual Report on Form 10-K for the year ended December 31, 2020 (“2020 Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on March 5, 2021 that have had a material impact on our condensed consolidated financial statements and related notes.

Forward-Looking Statements

Certain statements made in this Form 10-Q that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In many cases, you can identify forward-looking statements by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates,” or “plans” or the negative of these terms or other comparable terminology.

Forward-looking statements are based upon management’s beliefs, assumptions and current expectations concerning future events and trends, using information currently available, and are necessarily subject to uncertainties, many of which are outside our control. Although we believe that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at or by which any such performance or results will be achieved. A number of important factors could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. These factors include without limitation:

•impact of production, supply, contractual and other disruptions, including facility closures and furloughs, due to the spread of the COVID-19 pandemic;

•our ability to deliver products that meet changing technology and customer needs;

•our ability to successfully execute the strategic reorganization without significant disruption to our business;

•our ability to identify strategic acquisitions, to integrate such acquisitions into our business without disruption and to realize the anticipated benefits of such acquisitions;

•impact of future write-off or write-downs of goodwill and intangible assets;

•our ability to acquire and enforce intellectual property rights and defend such rights against third party claims;

•our ability to protect our intellectual property rights and confidential information, including our digital content, from third-party infringers or unauthorized copying, use or disclosure;

•failure of our information technology infrastructure or inability to protect against cyber-attack;

•our ability to generate net cash flow from operations;

•our ability to comply with the covenants in our borrowing agreements and maintain adequate borrowing capacity;

•impact of natural disasters, public health issues (including the COVID-19 pandemic), and other catastrophic events;

•impact of global economic, political and social conditions and financial markets on our business;

•fluctuations in our gross profit margins, operating income or loss and/or net income or loss;

•our ability to efficiently conduct business outside the U.S.;

•our dependence on our supply chain for components and sub-assemblies used in our 3D printers and other products and for raw materials used in our print materials;

•our ability to manage the costs and effects of litigation, investigations or similar matters involving us or our subsidiaries;

•product quality problems that result in decreased sales and operating margin, product returns, product liability, warranty or other claims;

•our ability to retain our key employees and to attract and retain new qualified employees, while controlling our labor costs;

•our exposure to product liability claims and other claims and legal proceedings;

•disruption in our management information systems for inventory management, distribution, and other key functions;

•compliance with U.S. and other anti-corruption laws, data privacy laws, trade controls, economic sanctions, and similar laws and regulations;

•our ability to comply with the terms of the Administrative Agreement with the U.S. Air Force and to maintain our status as a responsible contractor under federal rules and regulations;

•changes in, or interpretation of, tax rules and regulations;

•compliance with, and related expenses and challenges concerning, conflict-free minerals regulations; and

•the other factors discussed in the reports we file with or furnish to the SEC from time to time, including the risks and important factors set forth in additional detail in Item 1A. “Risk Factors” in the 2020 Form 10-K.

Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements included herein are made only as of the date of this Form 10-Q and we undertake no obligation to publicly update or revise any forward-looking statement made by us or on our behalf, whether as a result of new information, future developments, subsequent events or circumstances or otherwise, except as required by law. All subsequent written or oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

For a discussion of market risks at December 31, 2020, refer to Item 7A. “Quantitative and Qualitative Disclosures about Market Risk” in the 2020 Form 10-K. During the first six months of 2021, there were no material changes or developments that would materially alter the market risk assessment performed as of December 31, 2020.

Item 4. Controls and Procedures.

Evaluation of disclosure controls and procedures

As of June 30, 2021, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) pursuant to Rules 13a-15 and 15d-15 under the Exchange Act. These controls and procedures were designed to provide reasonable assurance that the information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, in a manner to allow timely decisions regarding required disclosures. Based on this evaluation, management has concluded that our disclosure controls and procedures were not effective as of June 30, 2021 because of the material weaknesses in internal control over financial reporting discussed below.

Our Chief Executive Officer and Chief Financial Officer have concluded that the following material weaknesses in internal control over financial reporting existed as of December 31, 2020 and are in the process of being remediated as of June 30, 2021:

•Lack of certain controls, or improper execution of designed control procedures, for certain non-standard contracts and non-standard contract terms, and

•Lack of certain controls, or improper execution of designed control procedures, over the review of internally prepared reports and analyses utilized in the financial closing process.

Remediation Plan

We are working to remediate the material weaknesses through the development and implementation of more formal policies, processes and documentation procedures relating to our financial reporting as well as the hiring of a Chief Accounting Officer (CAO), hiring additional accounting personnel and the training of new personnel and existing personnel in new roles on proper execution of designed control procedures. In addition, we engaged outside consultants to advise on changes in the design of our controls and procedures, implementation of our remediation activities and to advise on technical accounting matters. We believe that our remediation plan is sufficient to remediate the identified material weaknesses and strengthen our internal control over financial reporting. However, as we continue to evaluate, and work to improve, our internal control over financial reporting, management may determine that additional measures to address control deficiencies or modifications to the remediation plan are necessary. Therefore, we cannot provide assurance as to when the Company will remediate such weaknesses, nor can we be certain that additional actions will not be required or the costs of any such additional actions. Moreover, we cannot provide assurance that additional material weaknesses will not arise in the future.

Changes in Internal Control over Financial Reporting

As a result of the implementation of the material aspects of this remediation plan in the first half of 2021, including hiring a CAO, engaging outside consultants to advise on technical matters, implementing certain processes related to completeness and accuracy and beginning to train existing personnel on the execution of designed control procedures, there were changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

The information set forth in “Export Controls and Government Contracts Compliance Matter,” “Shareholder Suits,” and “Other” in Note 14 – Commitments and Contingencies to the Financial Statements in Part I, Item 1 of this Form 10-Q is incorporated herein by reference.

Item 1A. Risk Factors.

There are no material changes to the risk factors previously disclosed in our 2020 Form 10-K in response to Item 1A to Part I of Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Recent Issuances of Unregistered Securities

On May 5, 2021, the Company issued 157,045 shares of common stock to Illevax, Inc. (f/k/a Allevi, Inc.) (“Illevax”), pursuant to the terms of an Asset Purchase Agreement, for $3.5 million of consideration towards the purchase of all of the assets, properties and business of Illevax. The issuance of restricted stock was made in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act of 1933, and Rule 506 of Regulation D promulgated thereunder. Illevax is an “accredited investor” within the meaning of that term under to Rule 501 of Regulation D, who provided the Company with representations, warranties and information concerning their qualifications as an “accredited investor.” The Company provided and made available to Illevax full information regarding its business and operations. There was no general solicitation in connection with the offer or sale of the restricted securities. Illevax acquired the restricted common stock for their own account, for investment purposes and not with a view to public resale or distribution thereof within the meaning of the Securities Act. The restricted shares cannot be sold unless pursuant to an effective registration statement by the Company, or by an exemption from registration requirements of Section 5 of the Securities Act, the existence of any such exemption subject to legal review and approval by the Company.

Issuer Purchases of Equity Securities

The following table provides information about purchases of equity securities that are registered pursuant to Section 12 of the Exchange Act for the quarter ended June 30, 2021:


	Total number of shares (or units) purchased		Average price paid per share (or unit)
Shares delivered or withheld pursuant to restricted stock awards
April 1, 2021 - April 30, 2021	1,073		$	28.44
May 1, 2021 - May 31, 2021	159,680		$	22.73
June 1, 2021 - June 30, 2021	985		$	29.35
	161,738	(a)	$	22.81	(b)

a.Reflects shares of common stock surrendered to the Company for payment of tax withholding obligations in connection with the vesting of restricted stock.

b.The average price paid reflects the average market value of shares withheld for tax purposes.

Item 6. Exhibits.


2.1			Asset Purchase Agreement, dated June 1, 2021, by and among 3D Systems, Inc., Quickparts.com, Inc., 3D Systems Italia Srl, 3D Systems France Sarl, 3D Systems Europe Limited, 3D Systems GmbH, QP 3D Acquisition, Inc., and 3D Systems Corporation. (Incorporated by reference to Exhibit 2.1 of the Registrant’s Current Report on Form 8-K files on June 2, 2021.)

2.2			Stock Purchase Agreement, dated July 28, 2021, by and between 3D Systems, Inc. and Surgical Science Sweden AB. (Incorporated by reference to Exhibit 2.1 of the Registrant’s Current Report on Form 8-K files on July 30, 2021.)

10.1 *†			Employment Agreement, dated June 28, 2021, between 3D Systems Corporation and David K. Leigh.

3.1			Certificate of Incorporation of Registrant. (Incorporated by reference to Exhibit 3.1 to Form 8-B filed on August 16, 1993, and the amendment thereto, filed on Form 8-B/A on February 4, 1994.)

3.2			Amendment to Certificate of Incorporation filed on May 23, 1995. (Incorporated by reference to Exhibit 3.2 to Registrant’s Registration Statement on Form S-2/A, filed on May 25, 1995.)

3.3			Certificate of Amendment of Certificate of Incorporation filed with Secretary of State of Delaware on May 19, 2004. (Incorporated by reference to Exhibit 3.1 of the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2004, filed on August 5, 2004.)

3.4			Certificate of Amendment of Certificate of Incorporation filed with Secretary of State of Delaware on May 17, 2005. (Incorporated by reference to Exhibit 3.1 of the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2005, filed on August 1, 2005.)

3.5			Certificate of Amendment of Certificate of Incorporation filed with the Secretary of State of Delaware on October 7, 2011. (Incorporated by reference to Exhibit 3.1 to Form 8-K filed on October 7, 2011.)

3.6			Certificate of Amendment of Certificate of Incorporation filed with the Secretary of State of Delaware on May 21, 2013. (Incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K, filed on May 22, 2013.)

3.7			Amended and Restated By-Laws of 3D Systems Corporation. (Incorporated by reference to Exhibit 3.1 of Registrant’s Current Report on Form 8-K filed on March 15, 2018.)

31.1†			Certification of Principal Executive Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated August 9, 2021.

31.2†			Certification of Principal Financial Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated August 9, 2021.

32.1†			Certification of Principal Executive Officer filed pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 dated August 9, 2021.

32.2†			Certification of Principal Financial Officer filed pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 dated August 9, 2021.

101.INS†			XBRL Instance Document - the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document.

101.SCH†			XBRL Taxonomy Extension Schema Document.

101.CAL†			XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF†			XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB†			XBRL Taxonomy Extension Label Linkbase Document.

101.PRE†			XBRL Taxonomy Extension Presentation Linkbase Document.

104			Cover Page Interactive Data File - this data file does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document.

* Management contract or compensatory plan or arrangement

† Exhibits filed herein. All exhibits not so designated are incorporated by reference to a prior filing, as indicated.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


			3D Systems Corporation

			By			/s/ Jagtar Narula
						Jagtar Narula
						Chief Financial Officer
						(principal financial officer)



			By			/s/ Michael Crimmins
						Michael Crimmins
						Senior Vice President and Chief Accounting Officer
						(principal accounting officer)

Date: August 9, 2021